The preliminary safety findings from a Phase 1B clinical trial involving VRON-0200, a groundbreaking immunotherapy for chronic hepatitis B (HBV), were recently highlighted.
MapLight Therapeutics has initiated a Phase 1 clinical trial for ML-007/PAC, a novel combination therapy aimed at treating schizophrenia and Alzheimer's disease psychosis.
Gilead Sciences, Inc. and Xilio Therapeutics, Inc. have announced an exclusive license agreement for the development and commercialization of Xilio's tumor-activated IL-12 program, XTX301.
Aeovian Pharmaceuticals, focused on creating innovative therapeutics that target the mTORC1 pathway, has initiated its Phase 1 clinical trial for AV078.
May 17th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Eisai Begins Submission of Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) Subcutaneous Maintenance Dosing in Early Alzheimer's, Fast Track Status.
PTC Therapeutics, Inc. revealed today that the FDA has officially received the Biologics License Application for Upstaza™ (eladocagene exuparvovec), a gene therapy aimed at treating AADC deficiency.